We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eton Pharmaceuticals Inc | NASDAQ:ETON | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.07 | 1.90% | 3.75 | 3.71 | 4.04 | 3.92 | 3.69 | 3.69 | 69,162 | 22:16:11 |
From May 2022 to May 2024
By Colin Kellaher
Eton Pharmaceuticals Inc. on Friday said it has sold its hospital products to India's Dr. Reddy's Laboratories Ltd. for up to $50 million, as Eton pivots to exclusively focus on products that treat rare diseases.
The Deer Park, Ill., company received about $5 million at closing of the sale of its Biorphen, Rezipres and cysteine hydrochloride products, it said, adding that it is eligible to receive up to an additional $45 million based on the achievement of certain milestones.
The pharmaceutical company's commercial activities would now focus solely on rare-disease products with a portfolio of four candidates, two of which are currently FDA-approved commercial products, it said.
Trading in shares of Eton, which closed Thursday at $2.91, was halted premarket on Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 24, 2022 08:05 ET (12:05 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Eton Pharmaceuticals Chart |
1 Month Eton Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
